– “The recent sub-group analysis of the BTVA STEP-UP RCT1 shows very clearly that patients with collateral ventilation have significant and clinically meaningful improvement in lung function and quality life with a very low rate of major medical complications. In these patients, BTVA has been shown to have the best efficacy to safety profile, which is why BTVA is our first choice in patients with collateral ventilation. Additionally, the fact that BTVA can target disease at the segmental level is an advantage in certain patients due to the individual presentation of disease within a targeted lobe. We now have the therapies that allow us to assess each patient individually and offer the most effective treatment based on the presentation of their individual disease,” says Professor Ralf Eberhardt.

The BTVA InterVapor System is CE-Marked and approved for sale in the European Union. CAUTION: The BTVA InterVapor System is not approved for use in the United States.

Photo – http://mma.prnewswire.com/media/559868/Uptake_Medical_Algorithm_Infographic.jpg

(Immediapress – Adnkronos
Immediapress e’ un servizio di diffusione di comunicati stampa in testo originale redatto direttamente dall’ente che lo emette. Padovanews non e’ responsabile per i contenuti dei comunicati trasmessi.)